{"id":9513,"date":"2026-06-15T09:00:00","date_gmt":"2026-06-15T16:00:00","guid":{"rendered":"http:\/\/54.162.83.219\/?p=9513"},"modified":"2026-06-15T00:25:42","modified_gmt":"2026-06-15T07:25:42","slug":"daewoong-pharmaceutical-botox-rival","status":"publish","type":"post","link":"https:\/\/guru.today\/?p=9513","title":{"rendered":"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival"},"content":{"rendered":"\n<figure class=\"wp-block-image alignwide size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"875\" height=\"430\" src=\"http:\/\/54.162.83.219\/wp-content\/uploads\/daewoong.jpg\" alt=\"\" class=\"wp-image-9520\" srcset=\"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg 875w, https:\/\/guru.today\/wp-content\/uploads\/daewoong-300x147.jpg 300w, https:\/\/guru.today\/wp-content\/uploads\/daewoong-768x377.jpg 768w\" sizes=\"(max-width: 875px) 100vw, 875px\" \/><figcaption class=\"wp-element-caption\">(Photo=Daewoong Pharmaceutical)<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">For decades, South Korean pharmaceutical company Daewoong Pharmaceutical was best known at home for Ursa, a liver treatment that became a household name and one of the country\u2019s most recognizable drug brands.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Today, however, the company\u2019s growth story is increasingly being written outside South Korea\u2014and far beyond the liver-treatment market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Driven by the overseas success of Nabota, its botulinum toxin product marketed in the United States as Jeuveau, and the expansion of prescription drug Fexuclue, Daewoong Pharmaceutical is transforming itself from a domestically focused drugmaker into a company whose future depends increasingly on exports and specialty medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The shift reflects a broader evolution taking place across South Korea\u2019s pharmaceutical industry. Long overshadowed by the country\u2019s semiconductor, automotive and consumer electronics sectors, Korean drugmakers are increasingly seeking growth through innovative medicines and international markets rather than relying solely on domestic demand.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to company data, combined revenue from Ursa, Nabota and Fexuclue reached approximately $280 million last year, accounting for nearly one-third of Daewoong Pharmaceutical\u2019s standalone sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ursa remains an important pillar of the business. First introduced in 1961, the product generated about $66 million in revenue last year, reaching a record high more than six decades after its launch. Daewoong has extended the drug\u2019s commercial lifespan by expanding its medical applications and developing dosage-specific treatment strategies, allowing the product to maintain relevance in South Korea\u2019s prescription-drug market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yet the company\u2019s center of gravity has shifted decisively toward Nabota.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The botulinum toxin treatment generated approximately $150 million in sales last year, more than double Ursa\u2019s revenue and the highest annual figure in the product\u2019s history. More significantly, roughly 84% of Nabota sales came from overseas markets, highlighting how dependent the product has become on international demand.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The United States sits at the center of that strategy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nabota is sold in the U.S. through aesthetic medicine company Evolus under the brand name Jeuveau, competing in one of the world\u2019s most lucrative cosmetic injectable markets. The product has secured an estimated 14% share of the U.S. aesthetic toxin segment, giving Daewoong Pharmaceutical a meaningful presence in a market historically dominated by larger global competitors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For American investors and healthcare industry observers, the significance extends beyond a single product.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The success of Jeuveau demonstrates how a South Korean pharmaceutical company can leverage the U.S. market not only as a source of revenue but also as a platform for global expansion. Daewoong is now using its U.S. foothold to accelerate growth across Latin America and the Middle East and North Africa region, where it has already entered 10 countries.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company has set a goal of increasing Nabota\u2019s global revenue to approximately $330 million by 2030 through additional research and development investments and continued international expansion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the same time, Fexuclue, a prescription medicine developed by Daewoong Pharmaceutical, is emerging as another strategic growth driver as the company builds a portfolio less dependent on mature legacy products.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The result is a markedly different company from the one that built its reputation on a liver treatment prescribed primarily to Korean patients. While Ursa remains an enduring symbol of Daewoong Pharmaceutical\u2019s history, the company\u2019s future increasingly depends on whether products like Jeuveau can continue winning market share in the United States and other overseas markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For South Korea\u2019s pharmaceutical sector, Daewoong\u2019s transformation offers a glimpse of a larger ambition: turning locally developed medicines into globally recognized brands capable of competing in some of the industry\u2019s most profitable markets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For decades, South Korean pharmaceutical company Daewoong Pharmaceutical was best known at home for Ursa, a liver treatment<\/p>\n","protected":false},"author":7,"featured_media":9520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[38,28,54],"tags":[],"class_list":["post-9513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-stories","category-biz-beyond","category-top-section"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daewoong Pharmaceutical Botox Rival Expands Beyond Liver Medicine<\/title>\n<meta name=\"description\" content=\"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/guru.today\/?p=9513\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival\" \/>\n<meta property=\"og:description\" content=\"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/guru.today\/?p=9513\" \/>\n<meta property=\"og:site_name\" content=\"GURU TODAY\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T16:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"875\" \/>\n\t<meta property=\"og:image:height\" content=\"430\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jin Lee\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jin Lee\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513\"},\"author\":{\"name\":\"Jin Lee\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/person\\\/976030a4a8c104a0b509402bcb2a0631\"},\"headline\":\"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival\",\"datePublished\":\"2026-06-15T16:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513\"},\"wordCount\":601,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/daewoong.jpg\",\"articleSection\":[\"All Stories\",\"Biz &amp; Beyond\",\"Top section\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/guru.today\\\/?p=9513#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513\",\"url\":\"https:\\\/\\\/guru.today\\\/?p=9513\",\"name\":\"Daewoong Pharmaceutical Botox Rival Expands Beyond Liver Medicine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/daewoong.jpg\",\"datePublished\":\"2026-06-15T16:00:00+00:00\",\"description\":\"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/guru.today\\\/?p=9513\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#primaryimage\",\"url\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/daewoong.jpg\",\"contentUrl\":\"https:\\\/\\\/guru.today\\\/wp-content\\\/uploads\\\/daewoong.jpg\",\"width\":875,\"height\":430},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/guru.today\\\/?p=9513#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/guru.today\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/guru.today\\\/#website\",\"url\":\"https:\\\/\\\/guru.today\\\/\",\"name\":\"GURU TODAY\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/guru.today\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/guru.today\\\/#organization\",\"name\":\"GURU TODAY\",\"url\":\"https:\\\/\\\/guru.today\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/54.162.83.219\\\/wp-content\\\/uploads\\\/Logo_white-1.png\",\"contentUrl\":\"http:\\\/\\\/54.162.83.219\\\/wp-content\\\/uploads\\\/Logo_white-1.png\",\"width\":1000,\"height\":167,\"caption\":\"GURU TODAY\"},\"image\":{\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/guru.today\\\/#\\\/schema\\\/person\\\/976030a4a8c104a0b509402bcb2a0631\",\"name\":\"Jin Lee\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g\",\"caption\":\"Jin Lee\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daewoong Pharmaceutical Botox Rival Expands Beyond Liver Medicine","description":"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/guru.today\/?p=9513","og_locale":"en_US","og_type":"article","og_title":"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival","og_description":"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.","og_url":"https:\/\/guru.today\/?p=9513","og_site_name":"GURU TODAY","article_published_time":"2026-06-15T16:00:00+00:00","og_image":[{"width":875,"height":430,"url":"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg","type":"image\/jpeg"}],"author":"Jin Lee","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jin Lee","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/guru.today\/?p=9513#article","isPartOf":{"@id":"https:\/\/guru.today\/?p=9513"},"author":{"name":"Jin Lee","@id":"https:\/\/guru.today\/#\/schema\/person\/976030a4a8c104a0b509402bcb2a0631"},"headline":"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival","datePublished":"2026-06-15T16:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/guru.today\/?p=9513"},"wordCount":601,"commentCount":0,"publisher":{"@id":"https:\/\/guru.today\/#organization"},"image":{"@id":"https:\/\/guru.today\/?p=9513#primaryimage"},"thumbnailUrl":"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg","articleSection":["All Stories","Biz &amp; Beyond","Top section"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/guru.today\/?p=9513#respond"]}]},{"@type":"WebPage","@id":"https:\/\/guru.today\/?p=9513","url":"https:\/\/guru.today\/?p=9513","name":"Daewoong Pharmaceutical Botox Rival Expands Beyond Liver Medicine","isPartOf":{"@id":"https:\/\/guru.today\/#website"},"primaryImageOfPage":{"@id":"https:\/\/guru.today\/?p=9513#primaryimage"},"image":{"@id":"https:\/\/guru.today\/?p=9513#primaryimage"},"thumbnailUrl":"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg","datePublished":"2026-06-15T16:00:00+00:00","description":"Daewoong Pharmaceutical Botox rival strategy is gaining momentum as Nabota, sold in the U.S. as Jeuveau, drives overseas growth beyond Ursa liver medicine.","breadcrumb":{"@id":"https:\/\/guru.today\/?p=9513#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/guru.today\/?p=9513"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/guru.today\/?p=9513#primaryimage","url":"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg","contentUrl":"https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg","width":875,"height":430},{"@type":"BreadcrumbList","@id":"https:\/\/guru.today\/?p=9513#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/guru.today\/"},{"@type":"ListItem","position":2,"name":"A Korean Drugmaker Once Known for Liver Medicine Is Becoming a Global Botox Rival"}]},{"@type":"WebSite","@id":"https:\/\/guru.today\/#website","url":"https:\/\/guru.today\/","name":"GURU TODAY","description":"","publisher":{"@id":"https:\/\/guru.today\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/guru.today\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/guru.today\/#organization","name":"GURU TODAY","url":"https:\/\/guru.today\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/guru.today\/#\/schema\/logo\/image\/","url":"http:\/\/54.162.83.219\/wp-content\/uploads\/Logo_white-1.png","contentUrl":"http:\/\/54.162.83.219\/wp-content\/uploads\/Logo_white-1.png","width":1000,"height":167,"caption":"GURU TODAY"},"image":{"@id":"https:\/\/guru.today\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/guru.today\/#\/schema\/person\/976030a4a8c104a0b509402bcb2a0631","name":"Jin Lee","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cc12b8e87eae9a6dda21bcff42fc80e1452d3ec992f3e8c3338fab737401f71c?s=96&d=mm&r=g","caption":"Jin Lee"}}]}},"rttpg_featured_image_url":{"full":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",875,430,false],"landscape":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",875,430,false],"portraits":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",875,430,false],"thumbnail":["https:\/\/guru.today\/wp-content\/uploads\/daewoong-150x150.jpg",150,150,true],"medium":["https:\/\/guru.today\/wp-content\/uploads\/daewoong-300x147.jpg",300,147,true],"large":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",640,315,false],"1536x1536":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",875,430,false],"2048x2048":["https:\/\/guru.today\/wp-content\/uploads\/daewoong.jpg",875,430,false],"morenews-large":["https:\/\/guru.today\/wp-content\/uploads\/daewoong-825x430.jpg",825,430,true],"morenews-medium":["https:\/\/guru.today\/wp-content\/uploads\/daewoong-590x410.jpg",590,410,true]},"rttpg_author":{"display_name":"Jin Lee","author_link":"https:\/\/guru.today\/?author=7"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/guru.today\/?cat=38\" rel=\"category\">All Stories<\/a> <a href=\"https:\/\/guru.today\/?cat=28\" rel=\"category\">Biz &amp; Beyond<\/a> <a href=\"https:\/\/guru.today\/?cat=54\" rel=\"category\">Top section<\/a>","rttpg_excerpt":"For decades, South Korean pharmaceutical company Daewoong Pharmaceutical was best known at home for Ursa, a liver treatment","_links":{"self":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/9513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9513"}],"version-history":[{"count":1,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/9513\/revisions"}],"predecessor-version":[{"id":9521,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/posts\/9513\/revisions\/9521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=\/wp\/v2\/media\/9520"}],"wp:attachment":[{"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/guru.today\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}